论文部分内容阅读
目的:评价替格瑞洛在急性冠脉综合征(acute coronary syndrome,ACS)患者经皮冠状动脉介入治疗(percutaneous coronary intervention,PCI)术后的应用价值。方法:将我院收治的565例成功行PCI的急性冠脉综合征(acute coronary syndrome,ACS)患者随机分为2组:氯吡格雷组253例,术后口服氯吡格雷75 mg、QD;替格瑞洛组312例,术后口服替格瑞洛首剂180 mg,维持量90mg、BID。两组患者术后常规口服阿司匹林100 mg、QD。研究主要终点为主要不良心血管事件(major adverse cardiovascular events,MACE),包括全因死亡、靶血管血运重建和脑梗塞;次要终点为TIMI主要出血(定义为血红蛋白下降>50 g/L或颅内出血有关的临床显著出血事件)。结果:565例患者平均随访12个月,替格瑞洛组MACE发生率低于氯吡格雷组(3.8%vs.8.7%,P<0.05),两组TIMI主要出血事件发生率比较,差异无统计学意义(2.9%vs.3.2%,P>0.05)。结论:替格瑞洛能明显减少PCI术后主要不良心血管事件,并不增加主要出血。
Objective: To evaluate the value of ticagrelor in patients with acute coronary syndrome (ACS) after percutaneous coronary intervention (PCI). Methods: A total of 565 patients with acute coronary syndrome (ACS) who underwent PCI in our hospital were randomly divided into two groups: 253 patients in clopidogrel group and 75 mg oral clopidogrel QD; Ticagrelor group 312 cases, after oral administration of ticagrelor first dose of 180 mg, maintenance dose 90mg, BID. Two groups of patients after conventional oral aspirin 100 mg, QD. The primary endpoint of the study was major adverse cardiovascular events (MACE), including all-cause mortality, revascularization of the target vessel and cerebral infarction; the secondary end point was TIMI major bleeding (defined as hemoglobin drop> 50 g / L or Intracranial hemorrhage associated with clinically significant bleeding). Results: 565 patients were followed up for an average of 12 months. The incidence of MACE in ticagrelor group was lower than that in clopidogrel group (3.8% vs.8.7%, P <0.05). There was no significant difference in TIMI major bleeding between the two groups Statistical significance (2.9% vs.3.2%, P> 0.05). CONCLUSION: Ticagrelor significantly reduced major adverse cardiovascular events after PCI and did not increase major bleeding.